Efficacy and Safety of Eculizumab in Kidney Transplant Patients With Primary Atypical Hemolytic-Uremic Syndrome

González, Cristina Casas; López-Jiménez, Verónica; Vázquez-Sánchez, Teresa; Vázquez-Sánchez, Elena; Cabello, Mercedes; Hernández-Marrero, Domingo

doi:10.1016/j.transproceed.2021.09.063

Cited by 4 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regardless of the cause, aHUS is associated with a high rate of allograft loss. Hence, a high index of suspicion, prompt diagnosis and utilization of complement cascade inhibitors such as eculizumab are crucial for the maintenance of good allograft function [36][37][38][39]. The interruption of eculizumab in patients with aHUS after kidney transplantation remains controversial [40,41].…”

Section: Atypical Haemolytic Uremic Syndromementioning

confidence: 99%

The current therapeutic approach for anaemia after kidney transplant

Nissaisorakarn

Kantachuvesiri

2022

Current Opinion in Nephrology &Amp; Hypertension

View full text Add to dashboard Cite

Purpose of reviewAnaemia after kidney transplantation is a common finding with no uniform management guideline. Most approaches are derived from the chronic kidney disease (CKD) population. Recent advances for the treatment of anaemia in patients with CKD/End stage renal disease include hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHi), a novel class of oral erythropoietin-stimulating agents (ESAs). We present relevant studies of HIF-PHi in the transplant population and its implications on the management of posttransplant anaemia.Recent findingsData on HIF-PHi use in the kidney transplant population are promising. Limited data demonstrate a significant increase in haemoglobin, with a comparable safety profile to epoetin. Reported adverse effects include overcorrection and low iron stores.SummaryCurrent therapeutic approaches to anaemia in the kidney transplant population is mostly derived from the CKD population. More studies are needed on HIF-Phi, a novel class of ESAs that has thus far demonstrated promise in the kidney transplant population.

show abstract